- call +1-201-465-4211
- email sales@mrinsights.biz
Huntington's disease is an inherited disease that causes degeneration of nerve cells in the central nervous system (CNS). The disease has a broad impact on functional abilities of the human and usually results in movement and thinking disabilities. Most people with Huntington's disease develop signs and symptoms in their age of 30 to 40. When disease begins before age 20, the condition is known as juvenile Huntington's disease.
Scope of the Report:
This report focuses on the Huntington's Disease Therapeutics in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The demand for Huntington’s disease (HD) therapeutics as one of the primary growth factors for the Huntington’s disease therapeutics market. HD is equally prevalent in both males and females and affects people irrespective of their ethnicity. The disease symptoms may appear anytime in the individual’s life and the etiology is genetic. The person who inherits the mutated genes from their affected parents will probably suffer from the disease sometime in their lifetime.
The Americas is witnessing increasing incidences of HD. The availability of increased patient pool and the rise in government initiatives boost the research and development of novel therapeutics for the treatment of HD. The rising investments towards the launch of new drugs for the treatment of chorea will positively influence the growth of the Huntington’s disease therapeutics market in this region.
The worldwide market for Huntington's Disease Therapeutics is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new study.
Market Segment by Manufacturers, this report covers
F. Hoffmann-La Roche
H. Lundbeck
Prana Biotechnology
Teva Pharmaceutical Industries
Horizon Pharma
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Antidopaminergics
Anticonvulsants
Antipsychotics
Antidepressants
Market Segment by Applications, can be divided into
Hospitals
Clinics
Diagnostic Centers
There are 15 Chapters to deeply display the global Huntington's Disease Therapeutics market.
Chapter 1, to describe Huntington's Disease Therapeutics Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Huntington's Disease Therapeutics, with sales, revenue, and price of Huntington's Disease Therapeutics, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Huntington's Disease Therapeutics, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Huntington's Disease Therapeutics market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Huntington's Disease Therapeutics sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Huntington's Disease Therapeutics Introduction
1.2 Market Analysis by Type
1.2.1 Antidopaminergics
1.2.2 Anticonvulsants
1.2.3 Antipsychotics
1.2.4 Antidepressants
1.3 Market Analysis by Applications
1.3.1 Hospitals
1.3.2 Clinics
1.3.3 Diagnostic Centers
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 F. Hoffmann-La Roche
2.1.1 Business Overview
2.1.2 Huntington's Disease Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 F. Hoffmann-La Roche Huntington's Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 H. Lundbeck
2.2.1 Business Overview
2.2.2 Huntington's Disease Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 H. Lundbeck Huntington's Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Prana Biotechnology
2.3.1 Business Overview
2.3.2 Huntington's Disease Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Prana Biotechnology Huntington's Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Teva Pharmaceutical Industries
2.4.1 Business Overview
2.4.2 Huntington's Disease Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Teva Pharmaceutical Industries Huntington's Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Horizon Pharma
2.5.1 Business Overview
2.5.2 Huntington's Disease Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Horizon Pharma Huntington's Disease Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Huntington's Disease Therapeutics Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Huntington's Disease Therapeutics Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Huntington's Disease Therapeutics Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Huntington's Disease Therapeutics Manufacturer Market Share in 2017
3.3.2 Top 6 Huntington's Disease Therapeutics Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Huntington's Disease Therapeutics Market Analysis by Regions
4.1 Global Huntington's Disease Therapeutics Sales, Revenue and Market Share by Regions
4.1.1 Global Huntington's Disease Therapeutics Sales and Market Share by Regions (2013-2018)
4.1.2 Global Huntington's Disease Therapeutics Revenue and Market Share by Regions (2013-2018)
4.2 North America Huntington's Disease Therapeutics Sales and Growth Rate (2013-2018)
4.3 Europe Huntington's Disease Therapeutics Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Huntington's Disease Therapeutics Sales and Growth Rate (2013-2018)
4.5 South America Huntington's Disease Therapeutics Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Huntington's Disease Therapeutics Sales and Growth Rate (2013-2018)
5 North America Huntington's Disease Therapeutics by Countries
5.1 North America Huntington's Disease Therapeutics Sales, Revenue and Market Share by Countries
5.1.1 North America Huntington's Disease Therapeutics Sales and Market Share by Countries (2013-2018)
5.1.2 North America Huntington's Disease Therapeutics Revenue and Market Share by Countries (2013-2018)
5.2 United States Huntington's Disease Therapeutics Sales and Growth Rate (2013-2018)
5.3 Canada Huntington's Disease Therapeutics Sales and Growth Rate (2013-2018)
5.4 Mexico Huntington's Disease Therapeutics Sales and Growth Rate (2013-2018)
6 Europe Huntington's Disease Therapeutics by Countries
6.1 Europe Huntington's Disease Therapeutics Sales, Revenue and Market Share by Countries
6.1.1 Europe Huntington's Disease Therapeutics Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Huntington's Disease Therapeutics Revenue and Market Share by Countries (2013-2018)
6.2 Germany Huntington's Disease Therapeutics Sales and Growth Rate (2013-2018)
6.3 UK Huntington's Disease Therapeutics Sales and Growth Rate (2013-2018)
6.4 France Huntington's Disease Therapeutics Sales and Growth Rate (2013-2018)
6.5 Russia Huntington's Disease Therapeutics Sales and Growth Rate (2013-2018)
6.6 Italy Huntington's Disease Therapeutics Sales and Growth Rate (2013-2018)
7 Asia-Pacific Huntington's Disease Therapeutics by Countries
7.1 Asia-Pacific Huntington's Disease Therapeutics Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Huntington's Disease Therapeutics Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Huntington's Disease Therapeutics Revenue and Market Share by Countries (2013-2018)
7.2 China Huntington's Disease Therapeutics Sales and Growth Rate (2013-2018)
7.3 Japan Huntington's Disease Therapeutics Sales and Growth Rate (2013-2018)
7.4 Korea Huntington's Disease Therapeutics Sales and Growth Rate (2013-2018)
7.5 India Huntington's Disease Therapeutics Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Huntington's Disease Therapeutics Sales and Growth Rate (2013-2018)
8 South America Huntington's Disease Therapeutics by Countries
8.1 South America Huntington's Disease Therapeutics Sales, Revenue and Market Share by Countries
8.1.1 South America Huntington's Disease Therapeutics Sales and Market Share by Countries (2013-2018)
8.1.2 South America Huntington's Disease Therapeutics Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Huntington's Disease Therapeutics Sales and Growth Rate (2013-2018)
8.3 Argentina Huntington's Disease Therapeutics Sales and Growth Rate (2013-2018)
8.4 Colombia Huntington's Disease Therapeutics Sales and Growth Rate (2013-2018)
9 Middle East and Africa Huntington's Disease Therapeutics by Countries
9.1 Middle East and Africa Huntington's Disease Therapeutics Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Huntington's Disease Therapeutics Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Huntington's Disease Therapeutics Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Huntington's Disease Therapeutics Sales and Growth Rate (2013-2018)
9.3 UAE Huntington's Disease Therapeutics Sales and Growth Rate (2013-2018)
9.4 Egypt Huntington's Disease Therapeutics Sales and Growth Rate (2013-2018)
9.5 Nigeria Huntington's Disease Therapeutics Sales and Growth Rate (2013-2018)
9.6 South Africa Huntington's Disease Therapeutics Sales and Growth Rate (2013-2018)
10 Global Huntington's Disease Therapeutics Market Segment by Type
10.1 Global Huntington's Disease Therapeutics Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Huntington's Disease Therapeutics Sales and Market Share by Type (2013-2018)
10.1.2 Global Huntington's Disease Therapeutics Revenue and Market Share by Type (2013-2018)
10.2 Antidopaminergics Sales Growth and Price
10.2.1 Global Antidopaminergics Sales Growth (2013-2018)
10.2.2 Global Antidopaminergics Price (2013-2018)
10.3 Anticonvulsants Sales Growth and Price
10.3.1 Global Anticonvulsants Sales Growth (2013-2018)
10.3.2 Global Anticonvulsants Price (2013-2018)
10.4 Antipsychotics Sales Growth and Price
10.4.1 Global Antipsychotics Sales Growth (2013-2018)
10.4.2 Global Antipsychotics Price (2013-2018)
10.5 Antidepressants Sales Growth and Price
10.5.1 Global Antidepressants Sales Growth (2013-2018)
10.5.2 Global Antidepressants Price (2013-2018)
11 Global Huntington's Disease Therapeutics Market Segment by Application
11.1 Global Huntington's Disease Therapeutics Sales Market Share by Application (2013-2018)
11.2 Hospitals Sales Growth (2013-2018)
11.3 Clinics Sales Growth (2013-2018)
11.4 Diagnostic Centers Sales Growth (2013-2018)
12 Huntington's Disease Therapeutics Market Forecast (2018-2023)
12.1 Global Huntington's Disease Therapeutics Sales, Revenue and Growth Rate (2018-2023)
12.2 Huntington's Disease Therapeutics Market Forecast by Regions (2018-2023)
12.2.1 North America Huntington's Disease Therapeutics Market Forecast (2018-2023)
12.2.2 Europe Huntington's Disease Therapeutics Market Forecast (2018-2023)
12.2.3 Asia-Pacific Huntington's Disease Therapeutics Market Forecast (2018-2023)
12.2.4 South America Huntington's Disease Therapeutics Market Forecast (2018-2023)
12.2.5 Middle East and Africa Huntington's Disease Therapeutics Market Forecast (2018-2023)
12.3 Huntington's Disease Therapeutics Market Forecast by Type (2018-2023)
12.3.1 Global Huntington's Disease Therapeutics Sales Forecast by Type (2018-2023)
12.3.2 Global Huntington's Disease Therapeutics Market Share Forecast by Type (2018-2023)
12.4 Huntington's Disease Therapeutics Market Forecast by Application (2018-2023)
12.4.1 Global Huntington's Disease Therapeutics Sales Forecast by Application (2018-2023)
12.4.2 Global Huntington's Disease Therapeutics Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Huntington's Disease Therapeutics Picture
Table Product Specifications of Huntington's Disease Therapeutics
Figure Global Sales Market Share of Huntington's Disease
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
